Bioretec
Bioretec engineers safe, robust and reliable absorbable implants for both paediatric and adult orthopaedic care.
Funding rounds
6/2021, 2/2020, 9/2018
Springvest's ownership stake
0.1% (31 December 2025)
Sector
Life sciences
Exit type
Listed, 9/2021
Exit information
Bioretec, a developer of absorbable orthopaedic implants, listed its shares on the Nasdaq Helsinki First North Growth Market in autumn 2021. Following its listing, the company has strengthened its global presence, for example receiving FDA marketing approval in the United States for its trauma screw in 2023.
Investment multiple at exit
1.3x
In the 9/2018 round, the price per share was €1.50, in the 1/2020 round, the price per share was €1.80; and in the 6/2021 round, the price per share was €3.00. The closing price on listing day was €2.90.
Investment’s IRR
24% (9/2018), 32% (1/2020), -36% (6/2021)
Market value
Springvest funding in total
€13.2 million
Springvest remains a 0.1% shareholder in Bioretec.
